Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Completed · Phase 1

Conditions studied: Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes

In brief

This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activity.

Key facts

Study ID

NCT00246662

Run by

Sunesis Pharmaceuticals

People needed

75

Starts

2005-11-14

Expected to finish

2009-04-01

Last updated by the study team

2017-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• New Mexico Cancer Care Alliance — Albuquerque, New Mexico, United States
• University of Texas, MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.